Chemomab Therapeutics (CMMB) Receivables (2017 - 2019)
Chemomab Therapeutics' (CMMB) quarterly Receivables came in at $408000.0 in Q4 2019, down 88.08% YoY from $3.4 million in Q4 2018, and down 66.99% on a QoQ basis from $1.2 million in Q3 2019.
Chemomab Therapeutics (CMMB) Receivables (2017 - 2019) Analysis & Trends
Chemomab Therapeutics (CMMB) has 3 years of Receivables data on file, last reported at $408000.0 in Q4 2019.
- Quarterly Receivables fell 88.08% year-over-year to $408000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $408000.0 (down 88.08% YoY) and the FY2019 annual result came in at $408000.0, down 88.08% from the prior year.
- Receivables eased to $408000.0 in Q4 2019, from $1.2 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $3.4 million in Q4 2018 to a low of $408000.0 in Q4 2019.
- A 3-year average of $1.3 million and a median of $885000.0 in 2019 frame the typical range for Receivables.
- Annual changes were most pronounced in 2018 — Receivables jumped 725.06% — and 2019, when it plunged 88.08%.
- Tracing CMMB's Receivables over 3 years: stood at $415000.0 in 2017, then jumped by 725.06% to $3.4 million in 2018, then sank by 88.08% to $408000.0 in 2019.
- The last three Receivables figures came in at $408000.0 (Q4 2019), $1.2 million (Q3 2019), and $885000.0 (Q2 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | - |
| 10 | Chemomab Therapeutics | 13.20 Mn | 2.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 408,000.00 |
| Sep 30, 2019 | 1.24 Mn |
| Jun 30, 2019 | 885,000.00 |
| Dec 31, 2018 | 3.42 Mn |
| Dec 31, 2017 | 415,000.00 |